Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Tracking brain amyloid-β in presymptomatic Alzheimer's disease.

Jagust W.

Lancet Neurol. 2012 Dec;11(12):1018-20. doi: 10.1016/S1474-4422(12)70255-7. Epub 2012 Nov 6. No abstract available.

PMID:
23137951
2.

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.

Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM.

Lancet Neurol. 2012 Dec;11(12):1057-65. doi: 10.1016/S1474-4422(12)70227-2. Epub 2012 Nov 6.

3.

Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers.

Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN.

Brain. 2011 Jan;134(Pt 1):293-300. doi: 10.1093/brain/awq310. Epub 2010 Nov 16.

PMID:
21084313
4.

Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.

Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.

Int J Geriatr Psychiatry. 2015 May;30(5):505-13. doi: 10.1002/gps.4173. Epub 2014 Jul 7.

PMID:
25043833
5.

Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease: summary of primary findings and conclusions.

Pearson SD, Ollendorf DA, Colby JA.

JAMA Intern Med. 2014 Jan;174(1):133-4. doi: 10.1001/jamainternmed.2013.11711. Review. No abstract available.

PMID:
24081022
6.

PET and 18F ligands in the diagnosis of Alzheimer's disease.

Frisoni GB.

Lancet Neurol. 2011 May;10(5):397-9. doi: 10.1016/S1474-4422(11)70075-8. Epub 2011 Apr 8. No abstract available.

PMID:
21481641
7.

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.

Smith R, Wibom M, Olsson T, Hägerström D, Jögi J, Rabinovici GD, Hansson O.

J Alzheimers Dis. 2016;51(2):339-43. doi: 10.3233/JAD-151004.

PMID:
26836192
8.

Low Florbetapir PET Uptake and Normal Aβ1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier.

Lombardi G, Berti V, Tedde A, Bagnoli S, Piaceri I, Polito C, Lucidi G, Ferrari C, Ginestroni A, Moretti M, Pupi A, Nacmias B, Sorbi S.

J Alzheimers Dis. 2017;57(3):697-703. doi: 10.3233/JAD-161170.

PMID:
28304299
9.

Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model.

Waldron AM, Wyffels L, Verhaeghe J, Richardson JC, Schmidt M, Stroobants S, Langlois X, Staelens S.

J Alzheimers Dis. 2017;55(4):1537-1548. doi: 10.3233/JAD-160760.

10.

MR, (18)F-FDG, and (18)F-AV45 PET correlate with AD PSEN1 original phenotype.

Saint-Aubert L, Payoux P, Hannequin D, Barbeau EJ, Campion D, Delisle MB, Tafani M, Viallard G, Péran P, Puel M, Chollet F, Demonet JF, Pariente J.

Alzheimer Dis Assoc Disord. 2013 Jan-Mar;27(1):91-4. doi: 10.1097/WAD.0b013e318251d87c.

PMID:
22517194
11.

Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2013 Feb;27(5):1-4. No abstract available.

PMID:
23589929
12.

An imaging agent for amyloid.

[No authors listed]

Med Lett Drugs Ther. 2012 Jul 9;54(1394):54-5. No abstract available.

PMID:
22777304
13.

[Amyloid PET imaging with [18F]AV-45].

Tateno A, Okubo Y.

Nihon Rinsho. 2011 Oct;69 Suppl 8:561-4. Japanese. No abstract available.

PMID:
22787851
14.

Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.

Mattsson N, Tosun D, Insel PS, Simonson A, Jack CR Jr, Beckett LA, Donohue M, Jagust W, Schuff N, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Brain. 2014 May;137(Pt 5):1550-61. doi: 10.1093/brain/awu043. Epub 2014 Mar 12.

15.

Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease.

Kerbage C, Sadowsky CH, Tariot PN, Agronin M, Alva G, Turner FD, Nilan D, Cameron A, Cagle GD, Hartung PD.

Am J Alzheimers Dis Other Demen. 2015 Dec;30(8):738-45. doi: 10.1177/1533317513520214. Epub 2014 Feb 13.

PMID:
24526759
16.

GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F 18) for imaging beta-amyloid plaques in human brain.

Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, Yen TC, Jan TR, Skovronsky D, Kung MP, Wey SP.

Appl Radiat Isot. 2010 Dec;68(12):2293-7. doi: 10.1016/j.apradiso.2010.07.001. Epub 2010 Jul 7.

PMID:
20638295
17.

Florbetapir-PET imaging and postmortem beta-amyloid pathology.

Carome M, Wolfe S.

JAMA. 2011 May 11;305(18):1857; author reply 1857-8. doi: 10.1001/jama.2011.579. No abstract available.

PMID:
21558513
18.

Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.

Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM.

Semin Nucl Med. 2011 Jul;41(4):300-4. doi: 10.1053/j.semnuclmed.2011.03.001.

PMID:
21624563
19.

Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.

Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, Benedum TE, Kilbourn MR, Skovronsky D, Kung HF.

J Nucl Med. 2009 Nov;50(11):1887-94. doi: 10.2967/jnumed.109.065284. Epub 2009 Oct 16.

20.

Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.

Trembath L, Newell M, Devous MD Sr.

J Nucl Med Technol. 2015 Sep;43(3):175-84. doi: 10.2967/jnmt.115.156679. Epub 2015 Aug 13. Review.

Supplemental Content

Support Center